Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Ohar, Jill A ^a   Crater, Glenn D ^b   Emmett, Amanda ^b   Ferro, Thomas J ^b   Morris, Andrea N ^b   Raphiou, Ibrahim ^b   Sriram, Peruvemba S ^c   Dransfield, Mark T ^d  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL; TIOTROPIUM BROMIDE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG COMBINATION; FLUTICASONE, SALMETEROL DRUG COMBINATION; SALBUTAMOL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; INTENTION TO TREAT ANALYSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SELF REPORT; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84907273089     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-014-0105-2     Document Type: Article

References (41)

1. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007, 370:786-796. 10.1016/S0140-6736(07)61382-8, 17765528.
2. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, Yates JC, Calverley PM. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J 2012, 39:38-45. 10.1183/09031936.00194610, 21737561.
3. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138. 10.1056/NEJMoa0909883, 20843247.
4. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI. Changes in forced expiratory volume in 1 second over time in COPD. New Engl J Med 2011, 365:1184-1192. 10.1056/NEJMoa1105482, 21991892.
5. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852. 10.1136/thorax.57.10.847, 12324669.
6. Nishimura K, Sato S, Tsukino M, Hajiro T, Ikeda A, Koyama H, Oga T. Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2009, 7:69. 10.1186/1477-7525-7-69, 19624834.
7. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004, 23:698-702. 10.1183/09031936.04.00121404, 15176682.
8. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010, 19:113-118. 10.1183/09059180.00002610, 20956179.
9. Hurst JR, Donaldson GC, Quint JK, Goldring JJP, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179:368-374. 10.1164/rccm.200807-1067OC.
10. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012, 67:957-963. 10.1136/thoraxjnl-2011-201518, 22684094.
11. Halpin DMG, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung 2011, 189:261-268. 10.1007/s00408-011-9301-8, 21678045.
12. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1618-1623. 10.1164/ajrccm.164.9.2105011, 11719299.
13. Executive Summary: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease 2013,
14. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta2 agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003, 2:67-74. 10.1007/BF03256640, 14720023.
15. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Engl J Med 2007, 356:775-789. 10.1056/NEJMoa063070, 17314337.
16. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) on COPD exacerbations. Respir Med 2008, 102:1099-1108. 10.1016/j.rmed.2008.04.019, 18614347.
17. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009, 6(5):320-329. 10.1080/15412550903140881, 19863361.
18. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011, 183:323-329. 10.1164/rccm.201005-0762OC, 20813886.
19. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009, 34:95-102. 10.1183/09031936.00156508, 19164344.
20. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011, 12:146. 10.1186/1465-9921-12-146, 22054035.
21. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 152:S78-S121. 10.1164/ajrccm/152.5_Pt_2.S78.
22. Schünemann JH, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic Respiratory Questionnaire (CRQ). COPD 2005, 2:81-89. 10.1081/COPD-200050651, 17136967.
23. ADVAIR DISKUS®: Full Prescribing Information 2008,
24. Escarrabill J. Discharge planning and home care for end-stage COPD patients. Eur Respir J 2009, 34:507-512. 10.1183/09031936.00146308, 19648525.
25. Hernandez C, Jansa M, Vidal M, Nuñez M, Bertran MJ, Garcia-Aymerich J, Roca J. The burden of chronic disorders on hospital admissions prompts the need for new modalities of care: a cross-sectional analysis in a tertiary hospital. QJM 2009, 102:193-202. 10.1093/qjmed/hcn172, 19147657.
26. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1608-1613. 10.1164/ajrccm.161.5.9908022, 10806163.
27. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting β-agonists and inhaled corticosteroids vs long-acting β-agonists monotherapy for stable COPD. Chest 2009, 136:1029-1038. 10.1378/chest.09-0821, 19633090.
28. Readmissions Reduction Program 2013,
29. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. New Engl J Med 2009, 360:1418-1428. 10.1056/NEJMsa0803563, 19339721.
30. Hanania NA1, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003, 124:834-843. 10.1378/chest.124.3.834, 12970006.
31. Sethi S. Personalised medicine in exacerbations of COPD: the beginnings. Eur Respir J 2012, 40:1318-1319. 10.1183/09031936.00136412, 23204018.
32. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, Brightling CE. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012, 186:48-55. 10.1164/rccm.201108-1553OC, 22447964.
33. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005, 60:480-487. 10.1136/thx.2004.034280, 15923248.
34. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, Van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with Chronic Obstructive Pulmonary Disease: the COPE study. Am J Respir Crit Care Med 2002, 166:1858-1868. 10.1164/rccm.200206-512OC.
35. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146:545-555. 10.7326/0003-4819-146-8-200704170-00152, 17310045.
36. Short PM, Williamson PA, Elder DHJ, Lipworth SIW, Schembri S, Lipworth BJ. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest 2012, 141:81-86. 10.1378/chest.11-0038, 21799028.
37. Wedzicha JA1, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2007, 177:19-26. 10.1164/rccm.200707-973OC, 17916806.
38. Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest 2012, 141:396-405. 10.1378/chest.11-0495, 21835899.
39. Groenewegen KH, Postma DS, Hop WCJ, Wielders PLML, Schlösser NJJ, Wouters EFM. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133:350-357. 10.1378/chest.07-1342, 18198263.
40. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Müllerova H, Donaldson GC, Wedzicha JA. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007, 29:527-534. 10.1183/09031936.00092506, 17107990.
41. Fingleton J, Weatherall M, Beasley R. Towards individualised treatment in COPD. Thorax 2011, 66:363-364. 10.1136/thx.2010.155564, 21248321.